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The retroviral RNA genome encodes for three enzymes essential for virus replication: (i) the viral 
protease (PR), that converts the immature virion into a mature virus through the cleavage of precursor 
polypeptides; (ii) the reverse transcriptase (RT), responsible for the conversion of the single-stranded 
genomic RNA into double-stranded proviral DNA; and (iii) the integrase (IN) that inserts the proviral 
DNA into the host cell genome. All of them are important targets for therapeutic intervention. This 
Special Issue provides authoritative reviews on the most recent research towards a better 
understanding of structure-function relationships in retroviral enzymes. The Issue includes three 
reviews on retroviral PRs, seven on RT and reverse transcription, and four dedicated to viral 
integration.  
The viral PR plays a critical role at the last stage of viral replication by processing of Gag and Gag-
derived polyproteins at a limited number of sites. Detailed analysis of the substrate specificity of 
retroviral PRs reveals the existence of two types of cleavage sites with different specificities. 
However, it is not possible to give a consensus substrate sequence, based on known processing sites. 
Substrate specificity in retroviral PRs is addressed in the review by Tözsér [1]. Understanding the 
specificity of these enzymes should be helpful to design broad-spectrum inhibitors targeting human 
immunodeficiency virus type 1 (HIV-1) and other retroviruses. 
The approval of first-generation HIV-1 PR inhibitors such as saquinavir led to the introduction of 
highly active antiretroviral therapy (HAART) in 1995. HAART has been a revolutionary treatment 
towards the control of AIDS. However, antiviral drug resistance, deriving from viral replication 
mutability, and also the high price of PR inhibitors and problems of tolerability, toxicity and tolerance 
has triggered further research on HIV PRs. Second generation inhibitors designed to inhibit PRs 
resistant to first generation inhibitors have been developed to minimize side effects and improve 
dosing. Examples are lopinavir, atazanavir, tipranavir and darunavir. Developments in this area, as 
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well as descriptions of novel inhibitors in the pipeline, such as PL-100, brecanavir and GS 8374, and 
others targeting PR dimerization or the flaps are discussed in the review by Pokorná et al. [2]. 
The molecular mechanisms associated with PR inhibitor resistance, mediated by mutations that alter 
PR interactions with inhibitors or substrates, or dimer stability; as well as distal mutations that transmit 
changes to the active site of the enzyme are discussed in the light of the structural information 
available in the review authored by Weber and Agniswamy [3]. These authors show how structural 
data have provided guidelines towards the design of novel HIV PR inhibitors, such as GRL-02031 
based on darunavir. In those studies, it has been shown that the formation of hydrogen bonds between 
the drug and the backbone of the PR can be a valuable strategy for improving resilience to drug 
resistance, by favouring minimal changes in the PR backbone between wild-type and mutant enzymes 
[3]. 
The reverse transcription of the viral single-stranded (+) RNA genome into double-stranded DNA 
(dsDNA) is an essential step in retroviral replication, and therefore an important target for therapeutic 
intervention. Retroviral RTs have two distinct activities: (i) a DNA polymerase activity which uses 
either RNA or DNA as template; and (ii) an RNase H activity, which degrades RNA from RNA/DNA 
hybrids. HIV-1 RT is a heterodimer composed of two subunits of 66 kDa and 51 kDa, and the major 
target of anti-AIDS therapies. Singh et al. [4] provide a detailed account of the crystallographic work 
leading to our current knowledge of the HIV-1 RT structure and its mechanism of action. Their review 
focuses on the structural basis of RT inhibition by nucleoside and nonnucleoside RT inhibitors, with 
special attention to the effects of drug resistance mutations.  
Retroviral RTs are devoid of 3´5´ exonucleolytic proofreading activity and their mutation rates 
are around 10
-4 to 10
-5, well above the values reported for cellular DNA polymerases. Their 
contribution to mutagenesis, and therefore to the emergence of drug resistance is discussed in a review 
on the intrinsic fidelity of retroviral RTs [5]. In this review, the author provides an update on the 
molecular basis of fidelity of HIV-1 RT, based on published data obtained in vitro by using different 
methods, based either on the expression of genes such as lacZ or in measurements of nucleotide 
selectivity (e.g., the incorporation of correct versus incorrect nucleotides). 
Reverse transcription is a relatively complex process (reviewed in [6]) that initiates after binding of 
a specific cellular tRNA to the primer binding site (PBS) located in the 5´-end of the viral genome. 
The RT uses the tRNA as a primer and copies the 5´-end of the RNA genome in the so-called first (-) 
strand DNA synthesis. The synthesized RNA/DNA hybrid is degraded by the RNase H activity of the 
RT to generate the (-) strand single-stranded DNA (ssDNA). Reverse transcription initiation emerges 
as a distinct process with intervention of tRNA and viral proteins such as the nucleocapsid (NC) 
protein or Vif. In their review, Isel et al. [7] provide an update on our current understanding of the 
formation of the initiation complex of HIV-1 reverse transcription, paying special attention to the 
spatio-temporal regulation of the process and the participation of viral cofactors. 
The sequences at the 5´- and 3´-ends of the viral RNA genome are identical, and this characteristic 
allows the (-) strand ssDNA to hybridize with the 3´-end of the viral RNA. As DNA synthesis 
continues, RNase H degrades the RNA strand. A specific sequence, rich in purines (termed as 
polypurine tract or PPT) near the 3´-end of the viral RNA is relatively resistant to cleavage by RNase 
H and serves as primer for the synthesis of the second (+) strand of the DNA. Synthesis of (+) strand 
viral DNA is a tightly regulated process that can be reproduced in the laboratory in the absence of Viruses 2010, 2                  
 
 
1183
accessory viral and host factors. The communication between RT and the RNA/DNA hybrid is 
necessary to promote these events. The interaction between RT and its cognate PPT has been studied 
by using sophisticated biophysical techniques (e.g., chemical probing, mass spectrometry, NMR 
spectroscopy, and single molecule spectroscopy), and the obtained results are discussed in the review 
by Fabris et al. [8]. Synthesis of (+) strand DNA is followed by removal of the tRNA by the RNase H 
activity of the RT. A second transfer event, followed by extension of (+) and (-) strands leads to 
completion of proviral DNA synthesis. At both ends, proviral DNAs contain the same sequence 
(designated as long terminal repeats or LTRs).  
The role of the HIV-1 RNase H activity in reverse transcription, its structure and catalytic 
mechanisms, and potential ways to inhibit the enzyme are discussed in the review by Beilhartz and 
Götte [9]. Since none of the approved anti-HIV agents inhibit specifically the RNase H function of RT, 
the development of novel and potent antiviral agents targeting RNase H remains as a challenging 
opportunity for future research. 
Synthesis of proviral DNA is catalyzed by the viral RT, but other viral proteins such as NC play an 
important role as nucleic acid chaperones, during the strand transfers required to complete viral DNA 
synthesis [6]. Recent studies suggest that HIV-1 uses hundreds of cellular factors during the virus life 
cycle. The involvement of cellular proteins in the regulation of reverse transcription is discussed in the 
review by Warren et al. [10]. Cellular proteins such as HuR, AKAP149 and DNA topoisomerase I 
have been shown to interact with HIV-1 RT. In addition, Gemin2 and components of the Sin3a 
complex can also affect reverse transcription, through the interaction of the RT with the viral IN. 
Integration of the proviral DNA into the host chromosome is an essential step in the retroviral life 
cycle. The viral IN recognizes the two viral DNA ends and through relevant 3´-processing and strand 
transfer activities completes the integration reaction. In the review by Kessl et al. [11], the catalytic 
properties and structure of HIV-1 IN are discussed in the context of its interactions with the DNA, 
paying special attention to current research on the oligomeric forms of the enzyme, the role of its 
principal cofactor in HIV-1 and other retroviruses (i.e., lens epithelium derived growth factor, 
LEDGF/p75), and the characterization of relevant nucleoprotein complexes containing viral IN. 
Structural aspects of the interaction between LEDGF and lentiviral INs are specifically addressed by 
Hare and Cherepanov [12]. Several studies discussed in their review emphasize on the characteristic 
preference of lentiviruses to integrate within transcription units. It is now clear that the chromosomal 
site of viral integration is not random, and retroviruses display specific preferences at distinct genomic 
positions. Desfarges and Ciuffi [13] summarize current knowledge on retroviral integration site 
preferences and the mechanisms involved in the process. Again, a prominent role is given for 
LEDGF/p75, in combination with histone methyltransferases associated with active transcription. 
The last review of the Issue focuses on the contribution of host proteins to viral integration in the 
murine leukaemia virus (MLV) [14]. The functional equivalent of LEDGF/p75 in MLV is not known, 
perhaps reflecting a different nuclear entry mechanism used by HIV-1 versus MLV. However, there 
are many host factors that have been implicated in interactions with MLV pre-integration complexes. 
Examples include bona-fide and putative transcription factors (e.g., TFIIE-β, Ankrd49, Znfp38, ABT1, 
etc.), endonucleases (e.g., Fen1) or repair proteins (e.g., Ku70/XRCC6), among others. A better 
knowledge of MLV integration could be helpful to understand oncogene activation, and for designing 
better vectors to be used in gene therapy. Viruses 2010, 2                  
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I hope that this collection of reviews will contribute to a better knowledge of the field, while 
encouraging research and promoting interest in retroviral enzymes among graduate students and young 
scientists. Finally, I would like to thank authors for their valuable contributions and all reviewers for 
their constructive critiques. 
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